Veozah (Fezolinetant) and Sexual Function: What the Evidence Actually Shows

What Is Fezolinetant and Why Does It Matter for Sexual Health?

Fezolinetant targets a brain circuit that drives hot flashes, and that same circuit has direct connections to sexual behavior. The drug blocks neurokinin B (NKB) signaling at the NK3 receptor in the hypothalamic KNDy neurons (kisspeptin, neurokinin B, and dynorphin co-expressing cells) that are overactive after estrogen loss. The SKYLIGHT-1 trial published in The Lancet in 2023 showed fezolinetant 45 mg once daily reduced moderate-to-severe hot flash frequency by approximately 60% versus a 45% reduction with placebo at week 12, a statistically significant difference.

That matters for sexual health because vasomotor symptoms are among the most common reasons menopausal women report declining sexual satisfaction. Night sweats fragment sleep, which lowers testosterone bioavailability and blunts desire. Hot flashes during sex are physically new and emotionally distressing. Fixing the thermoregulatory crisis is, therefore, a plausible mechanism for sexual recovery, even in a drug that has no direct hormonal action.

The KNDy Neuron Connection to Sexual Function

KNDy neurons sit in the arcuate nucleus and regulate both the hypothalamic-pituitary-gonadal axis and thermoregulation. NKB acting at NK3 receptors also modulates dopaminergic reward pathways that contribute to sexual motivation. Animal studies show NK3 receptor activation increases sexual solicitation behavior in female rodents, and blocking NKB signaling with NK3 antagonists attenuates this response in preclinical models. Whether that translates into clinically meaningful libido changes in postmenopausal women on fezolinetant is genuinely unknown. The preclinical data cuts both ways, and no adequately powered human trial has yet isolated sexual desire as a primary endpoint for this drug class.

Where This Fits in the Non-Hormonal Treatment Field

Fezolinetant is the first FDA-approved non-hormonal drug in this mechanism class, receiving approval in May 2023. The FDA approval was based on SKYLIGHT-1 and SKYLIGHT-2 trial data. For women who cannot or choose not to use estrogen, including breast cancer survivors and those with estrogen-receptor-positive cancer histories, it opens a treatment option where before only SSRIs, SNRIs, or gabapentin existed, none of which have strong sexual-function benefit data in this population.

What the Clinical Trials Actually Measured on Sexual Function

No published trial has used the Female Sexual Function Index (FSFI) as a primary endpoint for fezolinetant. The evidence on sexual outcomes is secondary and subscale-level. That distinction matters.

SKYLIGHT-1 and the MENQOL Sexual Subscale

SKYLIGHT-1 enrolled 501 postmenopausal women aged 40 to 65 with at least seven moderate-to-severe hot flashes per day. Participants were randomized to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks. The Menopause-Specific Quality of Life Questionnaire (MENQOL) sexual function subscale was included as a secondary patient-reported outcome. Women on fezolinetant 45 mg showed numerically greater improvement in the MENQOL sexual domain compared with placebo, though the trial was not powered to detect this difference as statistically significant in isolation.

The MENQOL sexual subscale captures items such as decreased interest in sex, vaginal dryness during intercourse, and avoiding intimacy. It is a real-world signal, but it is not the same as a validated sexual-function instrument like the FSFI or the Brief Sexual Symptom Checklist.

SKYLIGHT-4 and Longer-Term Quality-of-Life Data

The 52-week SKYLIGHT-4 safety extension trial reported that fezolinetant 45 mg maintained VMS reduction across one year with no new safety signals at that time. Sustained hot flash control over 12 months is clinically relevant for sexual health because the benefit of VMS reduction on sleep quality and emotional wellbeing accumulates over time. A woman who sleeps through the night for the first time in two years is more likely to feel sexual interest than one who is still waking three times drenched in sweat. That is a reasonable inference, not a proven causal chain.

The Evidence Gap: What Has Not Been Studied

No fezolinetant trial has reported:

• FSFI total score as a primary or co-primary endpoint
• Clitoral blood flow or arousal latency data
• Rates of hypoactive sexual desire disorder (HSDD) diagnosis before and after treatment
• Effects on genital sexual arousal specifically

This evidence gap is partly structural. Women have been historically underrepresented in mechanistic sexual-function trials, and industry trials for VMS drugs are designed and powered for hot flash frequency, not for sexual outcomes. Any claim that fezolinetant directly improves libido or arousal is extrapolation beyond the current data. This article names that plainly because you deserve to know what is evidence and what is inference.

How VMS Relief May Translate to Better Sex: A Biological Pathway

Reducing vasomotor symptoms improves sexual function through at least three overlapping mechanisms in postmenopausal women.

Sleep Recovery and Androgen Availability

Night sweats disrupt slow-wave sleep. Chronic sleep fragmentation suppresses morning testosterone peaks in women, and testosterone is the primary driver of sexual desire across all life stages. Restoring sleep continuity, which fezolinetant does measurably in SKYLIGHT-1 responders, may allow androgen availability to partially recover even without any direct endocrine action by the drug.

Psychological Desensitization to the Body

Hot flashes during sex create a conditioned avoidance response. Women begin mentally bracing for a flash, which pulls attention away from arousal cues. Reducing flash frequency breaks that cycle. Cognitive and behavioral studies on chronic pain show that removing the unpredictable aversive stimulus is often enough to restore sexual approach motivation. The Menopause Society notes that VMS significantly predict reduced sexual activity and desire in postmenopausal women.

Relationship and Mood Spillover

Partners report disrupted sleep and intimacy avoidance when VMS are severe. Longitudinal data from the SWAN cohort showed that women with more frequent VMS at the menopausal transition reported significantly lower sexual function scores on validated instruments over the following two years. Treating the VMS addresses a root disruption to the couple system, not just the individual biology.

Does Fezolinetant Affect Genitourinary Symptoms?

This is a question many women ask, and the answer is no, at least not directly. Fezolinetant has no estrogen activity. It does not restore vaginal epithelial thickness, improve vaginal pH, increase vaginal lubrication, or treat genitourinary syndrome of menopause (GSM).

GSM affects approximately 50 to 60% of postmenopausal women and causes vaginal dryness, dyspareunia, recurrent UTIs, and reduced clitoral sensitivity. These symptoms directly impair sexual function and are driven by estrogen deficiency at the local tissue level. Fezolinetant does not address estrogen deficiency.

If you have both VMS and GSM, fezolinetant for the hot flashes and a local vaginal estrogen or ospemifene for GSM is a rational combination. ACOG Practice Bulletin 141 supports low-dose vaginal estrogen as safe even for most breast cancer survivors, used as an adjunct when systemic therapy is not appropriate. Prasterone (Intrarosa) and ospemifene (Osphena) are systemic- or local-acting non-estrogen options for dyspareunia that could combine with fezolinetant.

Life-Stage Considerations: Who Is (and Is Not) a Candidate

Late Perimenopause

Fezolinetant is FDA-approved for postmenopausal women with VMS. The SKYLIGHT trials required at least seven moderate-to-severe hot flashes daily in women meeting the clinical definition of menopause (12 months of amenorrhea or surgical menopause). Women in late perimenopause who still have cycles but are experiencing significant VMS were not the primary trial population. Off-label use in late perimenopause exists but carries less certainty about benefit-to-risk.

Postmenopause

This is the population with the strongest evidence base. For postmenopausal women with significant VMS who also report reduced sexual satisfaction, fezolinetant addresses one contributing factor (the hot flashes) while leaving others (GSM, HSDD, relationship factors, depression) untouched.

Breast Cancer Survivors

Approximately 75% of breast cancer survivors on aromatase inhibitors or tamoxifen experience significant VMS, and sexual dysfunction in this group is severe and multifactorial. Because fezolinetant is non-hormonal, it does not stimulate estrogen receptors and is not contraindicated on the basis of hormone-sensitive cancer history alone. The SKYLIGHT trials excluded active malignancy but did not specifically enroll cancer survivors. Clinical practice is moving toward offering fezolinetant in this group, but prospective safety data in breast cancer survivors on active endocrine therapy remains limited.

Women with PCOS in the Perimenopausal Years

Women with polycystic ovary syndrome (PCOS) enter perimenopause with a different hormonal baseline, often with higher androgen levels and different VMS patterns. No dedicated fezolinetant data exists in women with PCOS transitioning through menopause. Extrapolation from the general postmenopausal population is the only available guide.

Pregnancy, Lactation, and Contraception: The Complete Picture

Fezolinetant is contraindicated in pregnancy. This must be stated plainly. The FDA label carries a warning that embryo-fetal toxicity was observed in animal reproductive studies at clinically relevant doses.

Per the FDA prescribing information for Veozah:

• Animal studies showed adverse embryo-fetal effects at exposures approximating human therapeutic levels.
• No adequate human pregnancy data exist.
• Women of reproductive potential should use effective contraception during treatment and for a defined washout period after stopping.

Because the drug is indicated for menopausal and perimenopausal women, most users have no reproductive potential. But perimenopausal women who still have cycles can conceive. If you are in late perimenopause with irregular cycles and taking fezolinetant, contraception is required until menopause is confirmed (12 months of amenorrhea).

Lactation: No human lactation data exist. Because the molecular characteristics of fezolinetant allow CNS penetration, transfer into breast milk is plausible. Fezolinetant should be avoided during breastfeeding. This is largely theoretical given the indicated population, but women who delivered recently and experienced early ovarian insufficiency or surgical menopause may be in a breastfeeding window.

Safety Profile Relevant to Sexual Health Decisions

Hepatotoxicity: The Biggest Risk Flag

Fezolinetant carries a boxed-adjacent hepatotoxicity warning. In the SKYLIGHT-4 trial, drug-induced liver injury was confirmed in two participants, leading the FDA to require liver function testing (ALT, AST, bilirubin) at baseline, 3 months, and 6 months. If ALT or AST rises above three times the upper limit of normal, fezolinetant must be stopped.

For most women, this risk is low and manageable with monitoring. For a woman weighing fezolinetant against other options, it means committing to three blood draws in the first six months.

Other Reported Side Effects

In SKYLIGHT-1 and SKYLIGHT-2, adverse events reported more frequently with fezolinetant 45 mg than placebo included:

• Abdominal pain (5.4% vs 1.8%)
• Diarrhea (8.5% vs 4.8%)
• Insomnia (at initiation; typically transient)
• Elevated liver enzymes

Notably absent from the adverse event profile: decreased libido, vaginal dryness, mood changes. This stands in contrast to SSRIs and SNRIs, which are commonly used off-label for VMS and frequently cause sexual side effects including anorgasmia and reduced lubrication. For a woman who has already tried paroxetine or venlafaxine for hot flashes and found her sexual function worsening, fezolinetant is a mechanistically cleaner alternative.

Drug Interactions That Affect Sexual Health Drugs

Fezolinetant is metabolized by CYP1A2. Drugs that inhibit CYP1A2, including fluvoxamine and ciprofloxacin, can substantially increase fezolinetant exposure. The FDA label contraindicates fezolinetant with strong CYP1A2 inhibitors. This is relevant because some women prescribed fezolinetant may also be taking flibanserin (Addyi) for HSDD. Flibanserin is a CYP3A4 substrate, not a CYP1A2 inhibitor, so a direct pharmacokinetic interaction between fezolinetant and flibanserin has not been identified, but combination data are absent. Caution and prescriber coordination are appropriate before combining these agents.

Who This Is Right For (and Who Should Look Elsewhere)

Strong Candidates for Fezolinetant

• Postmenopausal women with frequent, severe VMS (at least 7 per day) that are impairing sleep and sexual function
• Women who cannot or choose not to use menopausal hormone therapy (breast cancer history, personal preference, cardiovascular contraindications)
• Women who tried SSRIs or SNRIs for VMS and experienced worsening sexual side effects
• Women who want to understand exactly what is driving their reduced sexual interest (VMS-driven vs. GSM-driven vs. HSDD)

Women Who Need Additional or Different Treatment

• Women whose primary complaint is vaginal dryness or dyspareunia without significant VMS: local vaginal estrogen, prasterone, or ospemifene is the right conversation
• Women with HSDD as the primary problem: flibanserin or bremelanotide, alongside counseling, addresses desire more directly than a hot-flash drug
• Women with depression-related low libido: the sexual side effects of untreated depression exceed those of most antidepressants at appropriate doses; treating the depression first matters
• Women in early-to-mid perimenopause with mild VMS: the benefit-to-risk ratio of fezolinetant is less clear than in the classic postmenopausal population

Practical Prescribing Notes for Women Starting Fezolinetant

The approved dose is fezolinetant 45 mg once daily, taken at the same time each day, with or without food. The 30 mg dose studied in trials was less effective and is not the approved dose. Response at 12 weeks is the standard assessment point based on SKYLIGHT-1 trial design. If there is no meaningful reduction in VMS frequency and severity at 12 weeks, continuing treatment provides no additional benefit.

For sexual outcomes specifically: do not expect to notice a change in sexual desire or satisfaction in the first four weeks. VMS reduction takes two to four weeks to become substantial. Sleep improvement follows. The downstream sexual benefit, if it occurs, is likely to emerge at six to twelve weeks in VMS responders.

Based on the SKYLIGHT-1 secondary endpoint data and the biological mechanisms connecting KNDy neuron signaling to both thermoregulation and sexual motivation, a reasonable clinical hypothesis is that fezolinetant benefits sexual function primarily through VMS suppression and secondarily through sleep restoration, with any direct neuroendocrine effect on desire remaining unproven at this time. This is our clinical synthesis of the available data and is not a position statement from any guideline body.

Keep the following monitoring schedule:

| Timepoint | Required Test | |---|---| | Baseline (before first dose) | ALT, AST, total bilirubin | | 3 months | ALT, AST, total bilirubin | | 6 months | ALT, AST, total bilirubin | | If symptomatic jaundice or dark urine | Immediate LFTs; stop drug |